文献速递病毒性肝炎

TLR7激动剂RO7020531与安慰剂在健康志愿者和慢性乙型肝炎病毒感染患者中的比较:一项随机、观察者盲法、安慰剂对照的1期试验

TLR7 agonist RO7020531 versus placebo in healthy volunteers and patients with chronic hepatitis B virus infection: a randomised, observer-blind, placebo-controlled, phase 1 trial.
PubMed 文献 · Lancet Infect Dis · 2022-12-09

这项随机、观察者盲法、安慰剂对照的1期试验在健康志愿者和慢性HBV感染患者中评估了TLR7激动剂RO7020531的安全性和耐受性。所有测试剂量在健康志愿者和患者中均安全且耐受性可接受,最常见治疗相关不良事件为头痛、流感样疾病和发热,多数不良事件为轻度和一过性。作者结论认为,由于安全性和耐受性可接受,RO7020531应继续开发用于慢性HBV感染患者的治疗。

要点

  • 在健康志愿者和慢性HBV感染患者中,RO7020531所有测试剂量均安全且耐受性可接受。
  • 总研究人群中最常见治疗相关不良事件为头痛(9%)、流感样疾病(4%)和发热(6%)。
  • 健康志愿者中无重度或严重不良事件;患者队列中报告1例重度不良事件和1例严重不良事件,无治疗相关死亡。

核心结论

  • 由于安全性和耐受性可接受,RO7020531应继续开发用于慢性HBV感染患者的治疗。

研究设计与样本

  • 随机、观察者盲法、安慰剂对照的1期试验,分两部分进行。
  • 第1部分在新西兰1个中心进行,健康志愿者按4:1随机分配至8个单次给药剂量队列(3 mg、10 mg、20 mg、40 mg、60 mg、100 mg、140 mg或170 mg)或3个多次给药剂量队列(100 mg、140 mg或170 mg,每2天1次,共13天)。
  • 第2部分在保加利亚、香港、意大利、新西兰、荷兰、台湾、泰国和英国的12个中心进行,核苷(酸)类似物抑制的慢性HBV感染患者在队列1-3(150 mg、150 mg或170 mg)按4:1随机分配,初治慢性HBV感染患者在队列4按3:1随机分配至150 mg RO7020531或安慰剂,每2天1次,共6周。
  • 主要结局为RO7020531的安全性和耐受性,通过不良事件的发生率和严重程度以及实验室、生命体征和心电图异常的发生率衡量,在所有接受至少一剂研究药物的参与者中分析。

主要发现

  • 2016年12月12日至2021年3月21日,第1部分筛查340名健康志愿者,其中80名随机分配至单次递增剂量研究(每个队列8名分配RO7020531,16名分配安慰剂),30名随机分配至多次递增剂量研究(每个队列8名分配RO7020531,6名分配安慰剂)。
  • 第2部分筛查110名患者,其中30名随机分配至队列1-3(16名分配RO7020531 150 mg,8名分配RO7020531 170 mg,6名分配安慰剂),20名随机分配至队列4(15名分配RO7020531,5名分配安慰剂)。
  • 总研究人群中最常见治疗相关不良事件为头痛(160名参与者中15名[9%])、流感样疾病(160名中7名[4%])和发热(160名中10名[6%])。
  • 多数不良事件为轻度和一过性;健康志愿者中无重度或严重不良事件。
  • 患者队列中报告1例重度不良事件(170 mg RO7020531的流感样疾病)和1例严重不良事件(接受RO7020531的初治患者发生中度流感样疾病并住院3天);无治疗相关死亡。

关键数值与推荐

  • 所有测试剂量的RO7020531在健康志愿者和患者中均安全且耐受性可接受。

临床怎么用

  • 作者结论认为,由于安全性和耐受性可接受,RO7020531应继续开发用于慢性HBV感染患者的治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Toll-like receptor 7 (TLR7) agonists augment immune activity and have potential for the treatment of chronic hepatitis B virus (HBV) infection. We aimed to assess the safety and tolerability of RO7020531 (also called RG7854), a prodrug of the TLR7 agonist RO7011785, in healthy volunteers and patients with chronic HBV infection. METHODS: This randomised, observer-blind, placebo-controlled, phase 1 study was done in two parts. Part 1 was done at one site in New Zealand and part 2 was done at 12 sites in Bulgaria, Hong Kong, Italy, New Zealand, the Netherlands, Taiwan, Thailand, and the UK. In part 1, healthy volunteers were randomly assigned (4:1) within one of eight dose cohorts (3 mg, 10 mg, 20 mg, 40 mg, 60 mg, 100 mg, 140 mg, or 170 mg) to receive a single RO7020531 dose or placebo or randomly assigned (4:1) within one of three dose cohorts (100 mg, 140 mg, or 170 mg) to receive either RO7020531 or placebo every other day for 13 days. In part 2, nucleoside or nucleotide analogue-suppressed patients with chronic HBV infection were randomly assigned (4:1) within cohorts 1-3 (150 mg, 150 mg, or 170 mg) to receive either RO7020531 or placebo and treatment-naive patients with chronic HBV infection were randomly assigned (3:1) in cohort 4 to receive either 150 mg of RO7020531 or placebo. Patients were treated every other day for 6 weeks. Study medication was administered orally to participants after they had fasted. Study participants and investigational staff were masked to treatment allocation. The primary outcome was the safety and tolerability of RO7020531, as measured by the incidence and severity of adverse events and the incidence of laboratory, vital sign, and electrocardiogram abnormalities, and was analysed in all participants who received at least one dose of the study medication. This trial is registered with ClinicalTrials.gov, NCT02956850, and the study is complete. FINDINGS: Between Dec 12, 2016, and March 21, 2021, 340 healthy volunteers were screened in part 1, of whom 80 were randomly assigned in the single ascending dose study (eight assigned RO7020531 in each cohort and 16 assigned placebo) and 30 were randomly assigned in the multiple ascending dose study (eight assigned RO7020531 in each cohort and six assigned placebo), and 110 patients were screened in part 2, of whom 30 were randomly assigned in cohorts 1-3 (16 assigned RO7020531 150 mg, eight assigned RO7020531 170 mg, and six assigned placebo) and 20 were randomly assigned in cohort 4 (15 assigned RO7020531 and five assigned placebo). All randomly assigned participants received at least one dose of a study drug and were included in the safety analysis. All tested doses of RO7020531 were safe and had acceptable tolerability in healthy volunteers and patients. The most frequent treatment-related adverse events among the total study population were headache (15 [9%] of 160 participants), influenza-like illness (seven [4%] of 160 participants), and pyrexia (ten [6%] of 160 participants). Most adverse events were mild and transient. There were no severe or serious adverse events in healthy volunteers. In the patient cohorts, there was one severe adverse event (influenza-like illness with 170 mg of RO7020531) and one serious adverse event (moderate influenza-like illness with a 3-day hospitalisation in a treatment-naive patient receiving RO7020531). There were no treatment-related deaths. INTERPRETATION: Due to acceptable safety and tolerability, RO7020531 should continue to be developed for the treatment of patients with chronic HBV infection. FUNDING: F Hoffmann-La Roche.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Yuen MF, Balabanska R, Cottreel E, et al. TLR7 agonist RO7020531 versus placebo in healthy volunteers and patients with chronic hepatitis B virus infection: a randomised, observer-blind, placebo-controlled, phase 1 trial. Lancet Infect Dis. 2022. PMID: 36509100. doi:10.1016/S1473-3099(22)00727-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。